CIPLA
Quarterly Results Analysis [Mar2024]
CIPLA Quarterly Results
Consolidated | Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹6,163 Cr | ₹6,604 Cr | ₹6,678 Cr | ₹6,329 Cr | ₹5,739 Cr | ₹5,810 Cr | ₹5,829 Cr | ₹5,375 Cr |
Expenses | ₹4,847 Cr | ₹4,856 Cr | ₹4,944 Cr | ₹4,835 Cr | ₹4,566 Cr | ₹4,403 Cr | ₹4,526 Cr | ₹4,232 Cr |
Operating Income | ₹1,316 Cr | ₹1,748 Cr | ₹1,734 Cr | ₹1,494 Cr | ₹1,174 Cr | ₹1,408 Cr | ₹1,302 Cr | ₹1,143 Cr |
Other Income | ₹249 Cr | ₹185 Cr | ₹176 Cr | ₹136 Cr | ₹135 Cr | ₹114 Cr | ₹123 Cr | ₹103 Cr |
Interest | ₹18 Cr | ₹30 Cr | ₹26 Cr | ₹16 Cr | ₹34 Cr | ₹32 Cr | ₹26 Cr | ₹18 Cr |
Depreciation | ₹288 Cr | ₹233 Cr | ₹290 Cr | ₹239 Cr | ₹346 Cr | ₹272 Cr | ₹299 Cr | ₹254 Cr |
Profit Before Tax | ₹1,259 Cr | ₹1,474 Cr | ₹1,594 Cr | ₹1,375 Cr | ₹745 Cr | ₹1,218 Cr | ₹1,100 Cr | ₹975 Cr |
Profit After Tax | ₹934 Cr | ₹1,069 Cr | ₹1,156 Cr | ₹997 Cr | ₹523 Cr | ₹808 Cr | ₹798 Cr | ₹707 Cr |
EPS | ₹11.63 | ₹13.08 | ₹14.01 | ₹12.33 | ₹6.51 | ₹9.92 | ₹9.78 | ₹8.51 |
Industry Peers & Returns | 1W | 1M | 1Y |
CIPLA | 3.5% | 4.2% | 51.8% |
SUN PHARMACEUTICAL INDUSTRIES | -0.9% | 0.9% | 62.6% |
DR REDDYS LABORATORIES | -1% | -2.4% | 28.4% |
ZYDUS LIFESCIENCES | 12.2% | 18% | 103.8% |
DIVIS LABORATORIES | 0.8% | 5.6% | 19.3% |
MANKIND PHARMA | -6.1% | -11.9% | 54.1% |
TORRENT PHARMACEUTICALS | 2.9% | 6.2% | 66.2% |
LUPIN | 1.5% | 4.2% | 109.2% |
AUROBINDO PHARMA | 3.1% | 7.9% | 81.3% |
CIPLA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -6.67 % |
Y-o-Y | 7.39 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹6,163 Cr | -6.67 | |
Dec2023 | ₹6,604 Cr | -1.11 | |
Sep2023 | ₹6,678 Cr | 5.52 | |
Jun2023 | ₹6,329 Cr | 10.27 | |
Mar2023 | ₹5,739 Cr | -1.22 | |
Dec2022 | ₹5,810 Cr | -0.32 | |
Sep2022 | ₹5,829 Cr | 8.43 | |
Jun2022 | ₹5,375 Cr | - |
CIPLA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -24.70 % |
Y-o-Y | 12.11 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹1,316 Cr | -24.70 | |
Dec2023 | ₹1,748 Cr | 0.79 | |
Sep2023 | ₹1,734 Cr | 16.05 | |
Jun2023 | ₹1,494 Cr | 27.28 | |
Mar2023 | ₹1,174 Cr | -16.61 | |
Dec2022 | ₹1,408 Cr | 8.08 | |
Sep2022 | ₹1,302 Cr | 13.90 | |
Jun2022 | ₹1,143 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -19.31 % |
Y-o-Y | 4.40 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 21.35% | -19.31 | |
Dec2023 | 26.46% | 1.93 | |
Sep2023 | 25.96% | 10.00 | |
Jun2023 | 23.6% | 15.40 | |
Mar2023 | 20.45% | -15.60 | |
Dec2022 | 24.23% | 8.46 | |
Sep2022 | 22.34% | 5.03 | |
Jun2022 | 21.27% | - |
CIPLA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -12.55 % |
Y-o-Y | 78.62 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹934 Cr | -12.55 | |
Dec2023 | ₹1,069 Cr | -7.55 | |
Sep2023 | ₹1,156 Cr | 15.98 | |
Jun2023 | ₹997 Cr | 90.51 | |
Mar2023 | ₹523 Cr | -35.26 | |
Dec2022 | ₹808 Cr | 1.29 | |
Sep2022 | ₹798 Cr | 12.91 | |
Jun2022 | ₹707 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -6.30 % |
Y-o-Y | 66.41 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 15.16 % | -6.30 | |
Dec2023 | 16.18 % | -6.53 | |
Sep2023 | 17.31 % | 9.90 | |
Jun2023 | 15.75 % | 72.89 | |
Mar2023 | 9.11 % | -34.51 | |
Dec2022 | 13.91 % | 1.61 | |
Sep2022 | 13.69 % | 4.19 | |
Jun2022 | 13.14 % | - |
CIPLA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -11.09 % |
Y-o-Y | 78.65 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹11.63 | -11.09 | |
Dec2023 | ₹13.08 | -6.64 | |
Sep2023 | ₹14.01 | 13.63 | |
Jun2023 | ₹12.33 | 89.40 | |
Mar2023 | ₹6.51 | -34.38 | |
Dec2022 | ₹9.92 | 1.43 | |
Sep2022 | ₹9.78 | 14.92 | |
Jun2022 | ₹8.51 | - |
You may also like the below Video Courses